Imagine a world

where days
are defined by
special moments

and balance is restored
to the lives of patients
and their families.

Our Story

We are a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs. The patient is at the core of every decision we make—from how we develop medicines, to the team we build that brings them to fruition—and we are resolved in our commitment to make a difference.

Hypoglycemia as a result of hyperinsulinism can strike in many forms. From infants with inherited disease to adults battling late-stage cancer, we are driven to empower individuals to restore balance within their lives, and we will continue to work with our partners around the world to fight hyperinsulinism in all its forms.

Disease Focus: Hyperinsulinism

Congenital hyperinsulinism (HI) is a rare genetic disease that presents very early in life and is characterized by excess and erratic insulin secretion that can cause infants, children, and adults to become dangerously hypoglycemic and starve their bodies of glucose.

Tumor hyperinsulinism (HI) may be caused by two distinct types of tumors: islet cell tumors (ICTs) and non-islet cell tumors (NICTs), both of which lead to hypoglycemia due to excessive activation of the insulin receptor.

Now enrolling

Phase III sunRIZE Trial in the study of congenital hyperinsulinism

sunrize-logo-wht

Latest News

Sep 19, 2024

Sep 09, 2024

Aug 27, 2024

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

Read More »

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

Read More »

Rezolute to Participate in Upcoming Investor Conferences

Read More »